StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.16−0.04 (-1.82%)

Close on Nov 17, 2026Market cap $103.14MP/E –Yield –

Minerva Neurosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Minerva Neurosciences's total debt was $1.33M at Jun 30, 2017. For fiscal 2016 it was $3.84M, down 54.8% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2016Dec 31, 2016$3.84M-54.8%
FY2015Dec 31, 2015$8.50M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2017Jun 30, 2017$1.33M–
Q1 FY2017Mar 31, 2017$2.60M–
Q4 FY2016Dec 31, 2016$3.84M–
Q3 FY2016Sep 30, 2016$5.05M–

More Minerva Neurosciences figures

See a number that looks wrong?